Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair

被引:176
作者
Lu, Yanxin [1 ]
Kwintkiewicz, Jakub [2 ,3 ]
Liu, Yang [1 ]
Tech, Katherine [4 ]
Frady, Lauren N. [2 ,3 ]
Su, Yu-Ting [1 ]
Bautista, Wendy [1 ]
Moon, Seog In [1 ]
MacDonald, Jeffrey [4 ]
Ewend, Matthew G. [2 ,3 ]
Gilbert, Mark R. [1 ]
Yang, Chunzhang [1 ]
Wu, Jing [1 ,2 ,3 ]
机构
[1] NCI, Neurooncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[3] Univ North Carolina Chapel Hill, Dept Neurosurg, Chapel Hill, NC USA
[4] Univ North Carolina Chapel Hill, Sch Med, Dept Biomed Engn, Chapel Hill, NC USA
关键词
MUTANT IDH1; ISOCITRATE DEHYDROGENASE; OLIGODENDROGLIAL TUMORS; ADJUVANT TEMOZOLOMIDE; GLIOBLASTOMA CELLS; PHASE-III; MUTATIONS; CANCER; INHIBITOR; SURVIVAL;
D O I
10.1158/0008-5472.CAN-16-2773
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations in isocitrate dehydrogenase (IDH) are the most prevalent genetic abnormalities in lower grade gliomas. The presence of these mutations in glioma is prognostic for better clinical outcomes with longer patient survival. In the present study, we found that defects in oxidative metabolism and 2-HG production confer chemosensitization in IDH1-mutated glioma cells. In addition, temozolomide (TMZ) treatment induced greater DNA damage and apoptotic changes in mutant glioma cells. The PARP1-associated DNA repair pathway was extensively compromised in mutant cells due to decreased NAD_ availability. Targeting the PARP DNA repair pathway extensively sensitized IDH1-mutated glioma cells to TMZ. Our findings demonstrate a novel molecular mechanism that defines chemosensitivity in IDH-mutated gliomas. Targeting PARP-associated DNA repair may represent a novel therapeutic strategy for gliomas.
引用
收藏
页码:1709 / 1718
页数:10
相关论文
共 38 条
[31]   Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial [J].
Stupp, Roger ;
Hegi, Monika E. ;
Mason, Warren P. ;
van den Bent, Martin J. ;
Taphoorn, Martin J. B. ;
Janzer, Robert C. ;
Ludwin, Samuel K. ;
Allgeier, Anouk ;
Fisher, Barbara ;
Belanger, Karl ;
Hau, Peter ;
Brandes, Alba A. ;
Gijtenbeek, Johanna ;
Marosi, Christine ;
Vecht, Charles J. ;
Mokhtari, Karima ;
Wesseling, Pieter ;
Villa, Salvador ;
Eisenhauer, Elizabeth ;
Gorlia, Thierry ;
Weller, Michael ;
Lacombe, Denis ;
Cairncross, J. Gregory ;
Mirimanoff, Rene-Olivier .
LANCET ONCOLOGY, 2009, 10 (05) :459-466
[32]   Mutational landscape and clonal architecture in grade II and III gliomas [J].
Suzuki, Hiromichi ;
Aoki, Kosuke ;
Chiba, Kenichi ;
Sato, Yusuke ;
Shiozawa, Yusuke ;
Shiraishi, Yuichi ;
Shimamura, Teppei ;
Niida, Atsushi ;
Motomura, Kazuya ;
Ohka, Fumiharu ;
Yamamoto, Takashi ;
Tanahashi, Kuniaki ;
Ranjit, Melissa ;
Wakabayashi, Toshihiko ;
Yoshizato, Tetsuichi ;
Kataoka, Keisuke ;
Yoshida, Kenichi ;
Nagata, Yasunobu ;
Sato-Otsubo, Aiko ;
Tanaka, Hiroko ;
Sanada, Masashi ;
Kondo, Yutaka ;
Nakamura, Hideo ;
Mizoguchi, Masahiro ;
Abe, Tatsuya ;
Muragaki, Yoshihiro ;
Watanabe, Reiko ;
Ito, Ichiro ;
Miyano, Satoru ;
Natsume, Atsushi ;
Ogawa, Seishi .
NATURE GENETICS, 2015, 47 (05) :458-U52
[33]   Extreme Vulnerability of IDH1 Mutant Cancers to NAD plus Depletion [J].
Tateishi, Kensuke ;
Wakimoto, Hiroaki ;
Iafrate, A. John ;
Tanaka, Shota ;
Loebe, Franziska ;
Lelic, Nina ;
Wiederschain, Dmitri ;
Bedel, Olivier ;
Deng, Gejing ;
Zhang, Bailin ;
He, Timothy ;
Shi, Xu ;
Gerszten, Robert E. ;
Zhang, Yiyun ;
Yeh, Jing-Ruey J. ;
Curry, William T. ;
Zhao, Dan ;
Sundaram, Sudhandra ;
Nigim, Fares ;
Koerner, Mara V. A. ;
Ho, Quan ;
Fisher, David E. ;
Roider, Elisabeth M. ;
Kemeny, Lajos V. ;
Samuels, Yardena ;
Flaherty, Keith T. ;
Batchelor, Tracy T. ;
Chi, Andrew S. ;
Cahill, Daniel P. .
CANCER CELL, 2015, 28 (06) :773-784
[34]   IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group [J].
van den Bent, Martin J. ;
Dubbink, Hendrikus J. ;
Marie, Yannick ;
Brandes, Alba A. ;
Taphoorn, Martin J. B. ;
Wesseling, Pieter ;
Frenay, Marc ;
Tijssen, Cees C. ;
Lacombe, Denis ;
Idbaih, Ahmed ;
van Marion, Ronald ;
Kros, Johan M. ;
Dinjens, Winand N. M. ;
Gorlia, Thierry ;
Sanson, Marc .
CLINICAL CANCER RESEARCH, 2010, 16 (05) :1597-1604
[35]   Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells [J].
Venere, M. ;
Hamerlik, P. ;
Wu, Q. ;
Rasmussen, R. D. ;
Song, L. A. ;
Vasanji, A. ;
Tenley, N. ;
Flavahan, W. A. ;
Hjelmeland, A. B. ;
Bartek, J. ;
Rich, J. N. .
CELL DEATH AND DIFFERENTIATION, 2014, 21 (02) :258-269
[36]   Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases [J].
Xu, Wei ;
Yang, Hui ;
Liu, Ying ;
Yang, Ying ;
Wang, Ping ;
Kim, Se-Hee ;
Ito, Shinsuke ;
Yang, Chen ;
Wang, Pu ;
Xiao, Meng-Tao ;
Liu, Li-xia ;
Jiang, Wen-qing ;
Liu, Jing ;
Zhang, Jin-ye ;
Wang, Bin ;
Frye, Stephen ;
Zhang, Yi ;
Xu, Yan-hui ;
Lei, Qun-ying ;
Guan, Kun-Liang ;
Zhao, Shi-min ;
Xiong, Yue .
CANCER CELL, 2011, 19 (01) :17-30
[37]   IDH1 and IDH2 Mutations in Gliomas [J].
Yan, Hai ;
Parsons, D. Williams ;
Jin, Genglin ;
McLendon, Roger ;
Rasheed, B. Ahmed ;
Yuan, Weishi ;
Kos, Ivan ;
Batinic-Haberle, Ines ;
Jones, Sian ;
Riggins, Gregory J. ;
Friedman, Henry ;
Friedman, Allan ;
Reardon, David ;
Herndon, James ;
Kinzler, Kenneth W. ;
Velculescu, Victor E. ;
Vogelstein, Bert ;
Bigner, Darell D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (08) :765-773
[38]   Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α [J].
Zhao, Shimin ;
Lin, Yan ;
Xu, Wei ;
Jiang, Wenqing ;
Zha, Zhengyu ;
Wang, Pu ;
Yu, Wei ;
Li, Zhiqiang ;
Gong, Lingling ;
Peng, Yingjie ;
Ding, Jianping ;
Lei, Qunying ;
Guan, Kun-Liang ;
Xiong, Yue .
SCIENCE, 2009, 324 (5924) :261-265